|
|
Profile
|
Delegates :
Jiro Kawada |
|
Incorporated :
February 7 , 2017 |
Paid in Capital :
10 Million yen |
Employees :
10 人 |
Address :
CYBERNICS MEDICAL INNOVATION BASE-A 322 3-25-16,tonomachi,Kawasaki-ku,Kawasaki-city,Kawasaki,Kanagawa KANAGAWA
〒210-0821
|
TEL/FAX :
044-381-7685 / |
URL：
https://www.jiksak.co.jp/ |
Attachment :
|
Mission/Background :
Jiksak Bioengineering, Inc. key businesses advances neurological therapeutics with innovative drug development and regenerative medicine technologies. The axon-integrated artificial nerve uses our Nerve OrganoidTM to create nerve tubes for peripheral nerve injury treatment and regeneration. Another proprietary technology, Drug Linked Carrier (DLC) are monoclonal antibodies linked to therapeutic molecules for neuron-selective drug delivery opens new possibilities for treatment of neurodegenerative diseases. |
|
Technology & Business
|
■Basic Technologies
1.Nerve Organoid™ Fabrication Technology:Our microfluidic devices generate Nerve Organoid™ in culture, contains 3D axon bundles, mimics nerves in human.This improves candidate compound prediction accuracy for neuronal drug efficacy and safety screening at preclinical stage.
2.Artificial Synapse Formation Technology:
Our synapse inducing microbeads stimulate pre-motor synapses formation in culture, empowering research and screening of candidate drugs for diseases with synaptic abnormalities.
■Core Businesses
1.Drug-Linked Carrier (DLC) technology:DLC technology deliver therapeutic molecules to peripheral motor nerves and central nervous system through neuromuscular junction of motor neurons. DLC allows minimally invasive and concentrated drug delivery to targeted neurons.
2.Medical Device Business:Nerve regeneration tubes device containing 3D axon bundles with the capacity to promote nerve reconstruction offers higher therapeutic efficacy compared to conventional treatments.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Drug Development: : DLC technology
|
Discovery
|
This technique targets drug uptake in peripheral motor nerves and central nervous system, with POC in small animals.
|
Acquire licensing partners (including joint R&D and technological improvements for eventual out-licensing)
|
Medical Device Development : Nerve allograft using iPS cells
|
Discovery
|
3D axon bundles of nerve organoid promote regeneration of severed nerves. Obtained POC in small animals and data published.
|
Acquire licensing partners (including joint R&D and technological improvements for eventual out-licensing)
|
Culture equipment sales: Nerve Organoid™ culture devices (A-Chip, B-chip, P-chip)
|
Launched
|
Three culture devices (A-chip, B-chip, P-chip) are available for selection based on purpose.
|
|
Technology Alliance: Nerve Organoid™ Fabrication Technology
|
Launched
|
Nerve organoid culture techniques using A-chip, B-chip, and P-chip. Proven in research papers and collaborative studies.
|
Acquire licensing partners (including joint R&D and technological improvements for eventual out-licensing)
|
Technology Alliance: Artificial Synapse Formation Technology
|
Launched
|
Neuron axons co-culture with microbeads showed synapse-like functionality. Collaborative research experience available
|
Acquire licensing partners (including joint R&D and technological improvements for eventual out-licensing)
|
|
Highlights
|
Basic Technologies
2024.07 A joint research agreement with Teijin Pharma. Two published papers related to NerveOrganoid（DOI: 0.1016/j.scr.2024.103493, DOI: 10.1016/j.crmeth.2024.100835 ）
Core Businesses
2023 Patent: 1 for a drug delivery, and 16 for antibodies for drug delivery.
2024 Joint research started with Tokyo University, on DLC research using disease models.
2024.02 Published a paper on drug efficacy in animals using axon-integrated artificial nerves (DOI: 10.1186/s41232-024-00319-4).
|
|
Alliance strategy
|
We are seeking partners for joint research and development or licensing opportunities. If you are interested in our technologies or business, please feel free to contact us through the web page below.
Contact:https://www.jiksak.co.jp/contact
|
|
|